false
0001419554
0001419554
2025-06-27
2025-06-27
0001419554
BBLG:CommonStockParValue0.001PerShareMember
2025-06-27
2025-06-27
0001419554
BBLG:WarrantsToPurchaseCommonStockParValue0.001PerShareMember
2025-06-27
2025-06-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 27, 2025
BONE
BIOLOGICS CORPORATION
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-40899 |
|
42-1743430 |
|
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
2 Burlington Woods Drive, Ste. 100
Burlington, MA |
|
01803 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (781) 552-4452
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 per share |
|
BBLG |
|
Nasdaq
Capital Market |
| |
|
|
|
|
| Warrants
to Purchase Common Stock, par value $0.001 per share |
|
BBLGW |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item
1.01 | Entry
Into a Material Definitive Agreement. |
On
June 27, 2025, Bone Biologics Corporation (the “Company”) priced a public offering (the “Offering”) of (i) 793,750
shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), together with Series
D warrants (the “Series D Warrants”) to purchase 793,750 shares of Common Stock and Series E warrants (the “Series
E Warrants,” together with the Series D Warrants, the “Warrants”) to purchase 793,750 shares of Common Stock at a combined
public offering price of $4.00 per Share and accompanying Warrants and (ii) pre-funded warrants (the “Pre-Funded Warrants”)
to purchase 456,250 shares of Common Stock, together with Series D Warrants to purchase 456,250 shares of Common Stock and Series E Warrants
to purchase 456,250 shares of Common Stock at a combined public offering price of $3.999 per Pre-Funded Warrant and accompanying Warrants.
Subject
to certain ownership limitations described in the Warrants, (i) the Series D Warrants have an exercise price of $4.00 per share of Common
Stock, are exercisable upon issuance and will expire five years from the date of issuance and (ii) the Series E Warrants have an exercise
price of $4.00 per share of Common Stock, are exercisable upon issuance and will expire eighteen months from the date of issuance. The
exercise price of the Warrants will be subject to adjustment for stock dividends, stock splits, reverse splits, and similar capital transactions
as described in the Warrants.
Each
Pre-Funded Warrant represents the right to purchase one share of Common Stock at an exercise price of $0.001 per share. Subject to certain
ownership limitations described in the Pre-Funded Warrants, the Pre-Funded Warrants are immediately exercisable and may be exercised
at any time until all of the Pre-Funded Warrants are exercised in full. In the event of a fundamental transaction, as described in the
Warrants and Pre-Funded Warrants, the holder will have the right to receive as alternative consideration, for each share of Common Stock
that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares
of common stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
receivable upon or as a result of such transaction by a holder of the number of shares of Common Stock for which the Series D Warrant,
Series E Warrant or Pre-Funded Warrant is exercisable immediately prior to such event. In the event of certain fundamental transactions,
holders of the Warrants will have the right to receive the Black Scholes Value of their Warrants calculated pursuant to a formula set
forth in the Warrants, payable either in cash or in the same type or form of consideration that is being offered and being paid to the
holders of Common Stock in such fundamental transaction.
A
holder will not have the right to exercise any portion of the Warrants or the Pre-Funded Warrants if the holder (together with its affiliates)
would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common Stock outstanding
immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrants
or the Pre-Funded Warrants.
In
connection with the Offering, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain
institutional investors. The Purchase Agreement contains customary representations and warranties of the Company, termination rights
of the parties, and certain indemnification obligations of the Company and ongoing covenants of the Company, including a prohibition
on issuance of Common Stock or securities convertible, exercisable or exchangeable into Common Stock by the Company for a period of 60
days after the closing date of the Offering and a prohibition on the Company entering into variable rate transactions for a period of
one year after the closing date of the Offering, subject to certain exceptions.
The
net proceeds to the Company from the Offering were approximately $4.3 million, after deducting Placement Agent’s (as defined below)
fees and other estimated offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Warrants,
if fully-exercised on a cash basis, will be approximately $10 million. The Company intends to use the net proceeds from the Offering
to fund clinical trials, maintain and extend its patent portfolio, and for working capital and other general corporate purposes.
The
Offering was made pursuant to the Company’s registration statement on Form S-1 (File No. 333-288282), which was declared effective
by the Securities and Exchange Commission on June 27, 2025, and a preliminary and final prospectus thereunder. The closing of the Offering
took place on June 30, 2025. After the closing of the Offering, the Company had 1,605,260 shares of Common Stock outstanding.
The
Company engaged H.C. Wainwright & Co., LLC (the “Placement Agent”) as the exclusive placement agent for the Offering.
The Placement Agent did not purchase or sell any securities, nor was it required to arrange the purchase or sale of any minimum number
or dollar amount of securities. The Placement Agent agreed to use its reasonable best efforts to arrange for the sale of the securities
in the Offering. The Company paid the Placement Agent an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company
from the Offering and a management fee equal to 1.0% of the aggregate gross proceeds from the Offering. The Company also reimbursed the
Placement Agent for non-accountable expenses in an amount up to $35,000, its legal fees and expenses and other out-of-pocket expenses
in the amount of up to $100,000, and its clearing expenses in the amount of $15,950. The Company also issued the Placement Agent or its
designees warrants to purchase up to 75,000 shares of Common Stock (or 6.0% of the aggregate number of Shares and Pre-Funded Warrants
sold in the Offering) (the “Placement Agent Warrants”). The Placement Agent Warrants have substantially the same terms
as the Warrants, except that the Placement Agent Warrants have an exercise price equal to $5.00 and have a term of five years from the
commencement of sales of the Offering.
The
foregoing is only a summary of the Series D Warrants, the Series E Warrants, the Pre-Funded Warrants, the Placement Agent Warrants and
the Purchase Agreement and does not purport to be a complete description thereof. Such descriptions are qualified in their entirety by
reference to the Form of Series D Warrant, the Form of Series E Warrant, the Form of Pre-Funded Warrant, the Form of Placement Agent
Warrant and the Form of Purchase Agreement, copies of which are incorporated by reference as Exhibits 4.1, 4.2, 4.3, 4.4 and 10.1, respectively,
to this Current Report on Form 8-K and are incorporated by reference herein.
On
June 27, 2025, the Company issued a press release announcing that the Company had priced the Offering. On June 30, 2025, the Company
issued a press release announcing the closing of the Offering. Copies of these press releases are attached hereto as Exhibit 99.1 and
99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.
| Item
9.01 | Financial
Statements and Exhibits. |
(d)
Exhibits
| Exhibit
No. |
|
Description |
| 4.1 |
|
Form of Series D Warrant dated June 30, 2025 |
| 4.2 |
|
Form of Series E Warrant dated June 30, 2025 |
| 4.3 |
|
Form of Pre-Funded Warrant dated June 30, 2025 |
| 4.4 |
|
Form of Placement Agent Warrant dated June 30, 2025 |
| 10.1* |
|
Form
of Securities Purchase Agreement dated June 27, 2025 |
| 99.1 |
|
Press
release dated June 27, 2025 |
| 99.2
|
|
Press release dated June 30, 2025 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
| |
|
|
| * |
|
Certain
information has been omitted from this exhibit in reliance upon Item 601(a)(5) of Regulation
S-K and will be furnished to the Securities and Exchange Commission upon request. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
|
BONE
BIOLOGICS CORPORATION |
| |
|
| Date:
June 30, 2025 |
|
|
| |
By: |
/s/
Jeffrey Frelick |
| |
|
Jeffrey
Frelick |
| |
|
Chief
Executive Officer |
